Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEVATE-1: Phase 1 dose-escalation study of CD19/CD20 T-cell engager GSK5926371 in B-cell driven autoimmune rheumatic diseases
jRCT2011250048Phase 1Recruiting
- Sponsor
- GSK
- Start
- Feb 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of GSK5926371 in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Autoimmune Myopathies and 2 more (2 arms), sponsored by GSK. Primary endpoints: Number of participants with adverse events and serious adverse events (Part 1) and Number of participants with adverse events and serious adverse events (Part 2). Started Feb 2026; status: recruiting.
02
Drugs
GSK5926371
03
Conditions
systemic lupus erythematosus (SLE)rheumatoid arthritis (RA)Autoimmune MyopathiesSjögren's syndromeautoimmune and inflammatory rheumatic disease (AIIRD)
Beyond the preview
Go deeper on jRCT2011250048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250048.